Scancell (LON:SCLP) Insider Martin Diggle Buys 3,150,000 Shares

Key Points

• Martin Diggle, an insider at Scancell Holdings plc, purchased 3,150,000 shares at an average price of GBX 9, totaling £283,500, on September 12th.
• Scancell has reported a 1-year low of GBX 7.26 and a 1-year high of GBX 18, with a current market capitalization of £101.39 million.
• The company expects to post a loss of -2.54 EPS for the current fiscal year, following recent earnings results of GBX (1.26) earnings per share.

Scancell Holdings plc (LON:SCLP - Get Free Report) insider Martin Diggle bought 3,150,000 shares of the business's stock in a transaction dated Friday, September 12th. The shares were bought at an average cost of GBX 9 per share, for a total transaction of £283,500.

Martin Diggle also recently made the following trade(s):

• On Thursday, August 7th, Martin Diggle bought 102,236 shares of Scancell stock. The stock was purchased at an average cost of GBX 11 per share, for a total transaction of £11,245.96.
• On Friday, August 1st, Martin Diggle bought 4,400,000 shares of Scancell stock. The shares were purchased at an average cost of GBX 10 per share, for a total transaction of £440,000.

Scancell Stock Down 1.2%

Scancell stock traded down GBX 0.12 during mid-day trading on Friday, hitting GBX 10.03. The company's stock had a trading volume of 764,845 shares, compared to its average volume of 1,035,308. The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The company has a market cap of £104.09 million, a PE ratio of -482.21 and a beta of 0.35. The firm's 50 day moving average is GBX 10.03 and its 200 day moving average is GBX 9.67. Scancell Holdings plc has a 52-week low of GBX 7.26 and a 52-week high of GBX 18.

Scancell (LON:SCLP - Get Free Report) last posted its quarterly earnings results on Thursday, September 11th. The company reported GBX (1.26) EPS for the quarter. On average, analysts anticipate that Scancell Holdings plc will post -2.5361112 earnings per share for the current year.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.